Illumina presents preliminary Q4/FY 2022 results at J.P. Morgan conference; no specific figures in filing

ILLUMINA, INC.

2022-FY EPS reported -$28.00 revenue$4,584,000,000

Announced preliminary financial results for Q4 and fiscal year ended Jan 1, 2023 during J.P. Morgan Healthcare Conference.
Filed transcript (Ex-99.1) and non-GAAP reconciliations (Ex-99.2, Ex-99.3) but actual revenue, EPS, or guidance figures not reproduced in the provided text.
No quantitative details on performance, segment results, or forward guidance are disclosed in the filing excerpts.
Investors would need to access the full webcast or transcript for the specific financial data referenced.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ILLUMINA, INC. reported preliminary financial results for fourth quarter and fiscal year ended January 1, 2023.

Period: fourth quarter and fiscal year ended January 1, 2023
Result: preliminary results

Exact text from the filing

On January 9, 2023, Illumina, Inc. (the "Company"), presented at the J.P. Morgan Healthcare Conference in San Francisco, California during which it discussed preliminary financial results for the fourth quarter and fiscal year ended January 1, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

ILLUMINA, INC. filing history →

Source: SEC EDGAR

accession 0001110803-23-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.